Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nutex Health (NUTX) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Nutex Health (NUTX) over the last 11 years, with Q3 2025 value amounting to $13.2 million.

  • Nutex Health's Share-based Compensation rose 56085.0% to $13.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $134.3 million, marking a year-over-year increase of 509250.57%. This contributed to the annual value of $16.6 million for FY2024, which is 48374.71% up from last year.
  • Nutex Health's Share-based Compensation amounted to $13.2 million in Q3 2025, which was up 56085.0% from $78.7 million recorded in Q2 2025.
  • In the past 5 years, Nutex Health's Share-based Compensation ranged from a high of $78.7 million in Q2 2025 and a low of -$14.1 million during Q2 2022
  • Over the past 5 years, Nutex Health's median Share-based Compensation value was $1.3 million (recorded in 2023), while the average stood at $8.0 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first plummeted by 37171.2% in 2021, then surged by 7884700.0% in 2025.
  • Quarter analysis of 5 years shows Nutex Health's Share-based Compensation stood at $4.0 million in 2021, then tumbled by 98.65% to $54166.0 in 2022, then skyrocketed by 1076.31% to $637159.0 in 2023, then skyrocketed by 2204.05% to $14.7 million in 2024, then decreased by 9.97% to $13.2 million in 2025.
  • Its Share-based Compensation was $13.2 million in Q3 2025, compared to $78.7 million in Q2 2025 and $27.6 million in Q1 2025.